Hepatitis Monthly

Published by: Kowsar

Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature

Seyed Mohsen Dehghani 1 , 2 , * , Seyed Ali Reza Taghavi 2 , Bita Geramizadeh 1 , Saman Nikeghbalian 1 , Nima Derakhshan 2 , Abdorrasoul Malekpour 2 and Seyed Ali Malek-Hosseini 1
Authors Information
1 Shiraz Transplant Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Gastroenterohepatology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: January 01, 2013, 13 (1); e6609
  • Published Online: January 1, 2013
  • Article Type: Research Article
  • Received: May 31, 2012
  • Revised: July 26, 2012
  • Accepted: December 28, 2012
  • DOI: 10.5812/hepatmon.6609

To Cite: Dehghani S M, Taghavi S A R, Geramizadeh B, Nikeghbalian S, Derakhshan N, et al. Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature, Hepat Mon. 2013 ;13(1):e6609. doi: 10.5812/hepatmon.6609.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64(1): 51-68[DOI]
  • 2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529-38[DOI][PubMed]
  • 3. Riediger C, Berberat PO, Sauer P, Gotthardt D, Weiss KH, Mehrabi A, et al. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transpl. 2007; 22
  • 4. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases. 2005; 5(9): 558-67[DOI]
  • 5. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001; 34(6): 903-10[DOI]
  • 6. Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest. 1992; 89(4): 1361-5[DOI][PubMed]
  • 7. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004; 10(8): 968-74[DOI][PubMed]
  • 8. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002; 35(6): 1528-35[DOI][PubMed]
  • 9. Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl. 2002; 8(1): 2-9[DOI][PubMed]
  • 10. Weinberger KM, Wiedenmann E, Bohm S, Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods. 2000; 85(1-2): 75-82[DOI]
  • 11. Wasmuth J. Hepatology. 2009;
  • 12. Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992; 33(10): 1390-6[DOI][PubMed]
  • 13. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992; 14(1): 104-11[DOI]
  • 14. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease. Hepatology. 1991; 13(4): 619-26[DOI]
  • 15. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 1995; 22(1): 36-43[DOI]
  • 16. Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology. 1988; 167(2): 630-3[DOI]
  • 17. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005; 11(4): 402-9[DOI][PubMed]
  • 18. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996; 61(9): 1358-64[DOI][PubMed]
  • 19. Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology. 1990; 12(2): 364-6[DOI][PubMed]
  • 20. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993; 329(25): 1842-7[DOI][PubMed]
  • 21. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005; 11(7): 716-32[DOI][PubMed]
  • 22. Wang YM, Tang YZ. Antiviral therapy for hepatitis B virus associated hepatic failure. Hepatobiliary Pancreat Dis Int. 2009; 8(1): 17-24[PubMed]
  • 23. Seehofer D, Rayes N, Neuhaus P. Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era. Expert Rev Anti Infect Ther. 2003; 1(2): 307-18[DOI][PubMed]
  • 24. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology. 1998; 27(1): 254-63[DOI][PubMed]
  • 25. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol. 1999; 30(4): 715-21[DOI]
  • 26. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007; 45(4): 1056-75[DOI][PubMed]
  • 27. Seehofer D, Rayes N, Berg T, Neuhaus R, Muller AR, Hopf U, et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int. 2000; 13(4): 290-6[DOI][PubMed]
  • 28. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998; 28(2): 585-9[DOI][PubMed]
  • 29. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol. 2003; 38(6): 811-7[DOI]
  • 30. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000; 6(4): 429-33[DOI][PubMed]
  • 31. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant. 2003; 17(3): 254-8[DOI][PubMed]
  • 32. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000; 6(6): 741-8[DOI][PubMed]
  • 33. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol. 2001; 34(6): 895-902[DOI]
  • 34. Seehofer D, Rayes N, Steinmuller T, Muller AR, Jonas S, Settmacher U, et al. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol. 2002; 40(9): 795-9[DOI][PubMed]
  • 35. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 2000; 32(1): 129-34[DOI][PubMed]
  • 36. Seehofer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation. 2005; 80(1 Suppl)-4[DOI][PubMed]
  • 37. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003; 125(2): 292-7[DOI]
  • 38. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004; 40(3): 719-26[DOI][PubMed]
  • 39. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002; 123(6): 1831-8[DOI][PubMed]
  • 40. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology. 2002; 36(2): 507-8[DOI][PubMed]
  • 41. Haberal M, Dalgic A. New concepts in organ transplantation. Transplant Proc. 2004; 36(5): 1219-24[DOI][PubMed]
  • 42. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: related risk factors and perspective. Hepatobiliary Pancreat Dis Int. 2005; 4(4): 502-8[PubMed]
  • 43. Ying C, De Clercq E, Neyts J. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. Antiviral Res. 2000; 48(2): 117-24[DOI]
  • 44. Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat. 1999; 6(3): 229-36[DOI][PubMed]
  • 45. Wu J, Xie HY, Jiang GP, Xu X, Zheng SS. The role of mycophenolate acid on HBV replication in vitro. Chin J Organ Transplant. 2003; 24: 310-2
  • 46. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol. 1998; 13(1): 14-20[DOI][PubMed]
  • 47. Shiota G, Harada K, Oyama K, Udagawa A, Nomi T, Tanaka K, et al. Severe exacerbation of hepatitis after short-term corticosteroid therapy in a patients with "latent" chronic hepatitis B. Liver. 2000; 20(5): 415-20[DOI][PubMed]
  • 48. Samuel D, Kimmoun E. Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Clinics in liver disease. 2003; 7(3): 667[DOI]
  • 49. Retrospective analysis of 30 patients who underwent liver transplantation without use of steroids. 1999;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments